BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition

Biochemical and Biophysical Research Communications

Volumn 425, Issue 2, 2012, Pages 328-332

  de Farias, Caroline Brunetto ^a,b,c   Heinen, Tiago Elias ^a,c   dos Santos, Rafael Pereira ^a,c   Abujamra, Ana Lucia ^a,b,c   Schwartsmann, Gilberto ^a,c   Roesler, Rafael ^a,b,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Children s Cancer Institute   (Brazil)

^c National Institute for Translational Medicine INCT TM   (Brazil)

Author keywords

Brain derived neurotrophic factor; Cetuximab; Colorectal cancer; Epidermal growth factor receptor; TrkB

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; K 252A;

ARTICLE; CELL PROTECTION; CELL STRAIN HT29; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HT29 CELLS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, TRKB; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 84865373544     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.091     Document Type: Article

References (25)

1. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C., Moore M.J., Zalcberg J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359:1757-1765.
2. Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 2010, 28:1254-1261.
3. Bardelli A., Jänne P.A. The road to resistance. EGFR mutation and cetuximab. Nat. Med. 2012, 18:199-200.
4. Diaz L.A., Williams R.T., Wu J., Kinde I., Hecht J.R., Berlin J., Allen B., Bozic I., Reiter J.G., Nowak M.A., Kinzler K.W., Oliner K.S., Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486:537-540.
5. Wheeler D.L., Huang S., Kruser T.J., Nechrebecki M.M., Armstrong E.A., Benavente S., Gondi V., Hsu K.T., Harari P.M. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008, 27:3944-3956.
6. Yonesaka K., Zejnullahu K., Okamoto I., Satoh T., Cappuzzo F., Souglakos J., Ercan D., Rogers A., Roncalli M., Takeda M., Fujisaka Y., Philips J., Shimizu T., Maenishi O., Cho Y., Sun J., Destro A., Taira K., Takeda K., Okabe T., Swanson J., Itoh H., Takada M., Lifshits E., Okuno K., Engelman J.A., Shivdasani R.A., Nishio K., Fukuoka M., Varella-Garcia M., Nakagawa K., Jänne P.A. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 2011, 3. 99ra86.
7. Bertotti A., Migliardi G., Galimi F., Sassi F., Torti D., Isella C., Corà D., Di Nicolantonio F., Buscarino M., Petti C., Ribero D., Russolillo N., Muratore A., Massucco P., Pisacane A., Molinaro L., Valtorta E., Sartore-Bianchi A., Risio M., Capussotti L., Gambacorta M., Siena S., Medico E., Sapino A., Marsoni S., Comoglio P.M., Bardelli A., Trusolino L. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011, 1:508-523.
8. Desmet C.J., Peeper D.S. The neurotrophic receptor TrkB: a drug target in anti-cancer therapy?. Cell. Mol. Life Sci. 2006, 63:755-759.
9. Thiele C.J., Li Z., McKee A.E. On Trk - the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin. Cancer Res. 2009, 15:5962-5967.
10. Roesler R., de Farias C.B., Abujamra A.L., Brunetto A.L., Schwartsmann G. BDNF/TrkB signaling as an anti-tumor target. Expert Rev. Anticancer Ther. 2011, 11:1473-1475.
11. Bardelli A., Parsons D.W., Silliman N., Ptak J., Szabo S., Saha S., Markowitz S., Willson J.K., Parmigiani G., Kinzler K.W., Vogelstein B., Velculescu V.E. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003, 300:949.
12. de Farias C.B., Rosemberg D.B., Heinen T.E., Koehler-Santos P., Abujamra A.L., Kapczinski F., Brunetto A.L., Ashton-Prolla P., Meurer L., Bogo M.R., Damin D.C., Schwartsmann G., Roesler R. BDNF/TrkB content and interaction with gastrin-releasing peptide receptor blockade in colorectal cancer. Oncology 2010, 79:430-439.
13. Akil H., Perraud A., Mélin C., Jauberteau M.O., Mathonnet M. Fine-tuning roles of endogenous brain-derived neurotrophic factor, TrkB and sortilin in colorectal cancer cell survival. PLoS One 2011, 6:e25097.
14. Flores D.G., de Farias C.B., Leites J., de Oliveira M.S., Lima R.C., Tamajusuku A.S., Di Leone L.P., Meurer L., Brunetto A.L., Schwartsmann G., Lenz G., Roesler R. Gastrin-releasing peptide receptors regulate proliferation of C6 glioma cells through a phosphatidylinositol 3-kinase-dependent mechanism. Curr. Neurovasc. Res. 2008, 5:99-105.
15. de Farias C.B., Lima R.C., Lima L.O., Flores D.G., Meurer L., Brunetto A.L., Schwartsmann G., Roesler R. Stimulation of proliferation of U138-MG glioblastoma cells by gastrin-releasing peptide in combination with agents that enhance cAMP signaling. Oncology 2008, 75:27-31.
16. Allegra C.J., Jessup J.M., Somerfield M.R., Hamilton S.R., Hammond E.H., Hayes D.F., McAllister P.K., Morton R.F., Schilsky R.L. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 2009, 27:2091-2096.
17. Misale S., Yaeger R., Hobor S., Scala E., Janakiraman M., Liska D., Valtorta E., Schiavo R., Buscarino M., Siravegna G., Bencardino K., Cercek A., Chen C.T., Veronese S., Zanon C., Sartore-Bianchi A., Gambacorta M., Gallicchio M., Vakiani E., Boscaro V., Medico E., Weiser M., Siena S., Di Nicolantonio F., Solit D., Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
18. Sartore-Bianchi A., Martini M., Molinari F., Veronese S., Nichelatti M., Artale S., Di Nicolantonio F., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S., Bardelli A. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009, 69:1851-1857.
19. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., Kalogeras K.T., Kotoula V., Papamichael D., Laurent-Puig P., Penault-Llorca F., Rougier P., Vincenzi B., Santini D., Tonini G., Cappuzzo F., Frattini M., Molinari F., Saletti P., De Dosso S., Martini M., Bardelli A., Siena S., Sartore-Bianchi A., Tabernero J., Macarulla T., Di Fiore F., Gangloff A.O., Ciardiello F., Pfeiffer P., Qvortrup C., Hansen T.P., Van Cutsem E., Piessevaux H., Lambrechts D., Delorenzi M., Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010, 11:753-762.
20. Martin-Zanca D., Mitra G., Long L.K., Barbacid M. Molecular characterization of the human trk oncogene. Cold Spring Harb. Symp. Quant. Biol. 1986, 51(Pt 2):983-992.
21. Huang E.J., Reichardt L.F. Trk receptors: roles in neuronal signal transduction. Annu. Rev. Biochem. 2003, 72:609-642.
22. Li Z., Oh D.Y., Nakamura K., Thiele C.J. Perifosine-induced inhibition of akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo. Cancer 2011, 117:5412-5422.
23. Geiger T.R., Song J.Y., Rosado A., Peeper D.S. Functional characterization of human cancer-derived TRKB mutations. PLoS One 2011, 6:e16871.
24. Fujikawa H., Tanaka K., Toiyama Y., Saigusa S., Inoue Y., Uchida K., Kusunoki M. High TrkB expression levels are associated with poor prognosis and EMT induction in colorectal cancer cells. J. Gastroenterol. 2012, 10.1007/s00535-012-0532-0.
25. Spano J.P., Fagard R., Soria J.C., Rixe O., Khayat D., Milano G. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann. Oncol. 2005, 16:189-194.